![]() ![]() The exact cause of death is unknown, but cardiac arrest following an unexpected development of a severe acute asthmatic crisis and subsequent hypoxia is suspected. Therefore, VENTOLIN HFA, like all other sympathomimetic amines, should be used with caution in patients with underlying cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.įatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma. The clinical relevance of these findings is unknown. ![]() In addition, beta-agonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. If such effects occur, VENTOLIN HFA may need to be discontinued. VENTOLIN HFA, like all other beta2 -adrenergic agonists, can produce clinically significant cardiovascular effects in some patients such as changes in pulse rate or blood pressure. Early consideration should be given to adding anti-inflammatory agents, e.g., corticosteroids, to the therapeutic regimen. The use of beta-adrenergic agonist bronchodilators alone may not be adequate to control asthma in many patients. If the patient needs more doses of VENTOLIN HFA than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. It should be recognized that paradoxical bronchospasm, when associated with inhaled formulations, frequently occurs with the first use of a new canister.Īsthma may deteriorate acutely over a period of hours or chronically over several days or longer. If paradoxical bronchospasm occurs following dosing with VENTOLIN HFA, it should be discontinued immediately and alternative therapy should be instituted. VENTOLIN HFA can produce paradoxical bronchospasm, which may be life threatening. VENTOLIN HFA is contraindicated in patients with a history of hypersensitivity to any of the ingredients. Each actuation delivers 108 mcg of albuterol sulfate (90 mcg of albuterol base) from the mouthpiece. Blue plastic inhaler with a blue strapcap containing a pressurized metered-dose aerosol canister containing 60 or 200 metered inhalations and fitted with a counter. To prime VENTOLIN HFA, release 4 sprays into the air away from the face, shaking well before each spray.Ĭleaning: To ensure proper dosing and to prevent actuator orifice blockage, wash the actuator with warm water and let it air-dry completely at least once a week. Prime VENTOLIN HFA before using for the first time, when the inhaler has not been used for more than 2 weeks, or when the inhaler has been dropped. Priming: Priming VENTOLIN HFA is essential to ensure appropriate albuterol content in each actuation. VENTOLIN HFA should be administered by the orally inhaled route only. More frequent administration or a greater number of inhalations is not recommended.įor prevention of exercise-induced bronchospasm, the usual dosage for adults and children aged 4 years and older is 2 inhalations 15 to 30 minutes before exercise. VENTOLIN HFA is indicated for the prevention of exercise-induced bronchospasm in patients aged 4 years and older.įor treatment of acute episodes of bronchospasm or prevention of symptoms associated with bronchospasm, the usual dosage for adults and children is 2 inhalations repeated every 4 to 6 hours in some patients, 1 inhalation every 4 hours may be sufficient. VENTOLIN® HFA Inhalation Aerosol is indicated for the treatment or prevention of bronchospasm in patients aged 4 years and older with reversible obstructive airway disease. ![]() VENTOLIN HFA- albuterol sulfate aerosol, metered ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |